Vasuda Healthcare Analytics initiated coverage of NewLink Genetics Corp. (Nasdaq: NLNK) with a Buy rating and a $24 price target. Shares of the biopharmaceutical leaped $3.02 to close at $19.02.
NewLink Genetics initiated with Buy rating
April 19, 2017 at 17:21 PM EDT
